CAR T-Cell trial for rare lymphoma halted after just one patient
NCT ID NCT06912529
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated early and only enrolled one person, so we have very little information from it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axicabtagene ciloleucel (CAR T-cells)
- What this could lead to
- If successful, this could provide a second-line treatment option for patients with relapsed or refractory primary mediastinal B-cell lymphoma.
- What could go wrong
- The trial was terminated early with only 1 participant enrolled, so results are very limited. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster
Münster, 48149, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a single shot build a cancer army inside the body?
- Engineered immune cells take on stubborn lymphoma
- Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
- New hope for tough lymphomas: balstilimab trial opens
- Which Pre-CAR-T chemo is safer? new trial aims to find out